Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Merrimack Pharmaceuticals

Market Cap 224M 193M 177M 167M 313M 21.15B 316M 2.1B 820M 10.36B 840M 822M 35.83B P/E Ratio 2022
-100x
P/E Ratio 2023 -162x
Enterprise Value 205M 177M 163M 152M 286M 19.36B 289M 1.92B 750M 9.48B 769M 753M 32.81B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
98.81%
Yield 2022 *
-
Yield 2023 -
3 years 11.53
Extreme 11.53
15.89
5 years 3
Extreme 3
15.89
10 years 1.49
Extreme 1.49
67.9
Manager TitleAgeSince
Chief Executive Officer 74 28/06/2019
Investor Relations Contact - -
Director TitleAgeSince
Chairman 74 01/01/2005
Date Insider Type Main position Quantity % Market Cap.
26/12/23
Western Standard LLC
BuyCompany 49,550 0.3460%
07/12/23
Western Standard LLC
BuyCompany 101,050 0.7056%
17/11/23
Western Standard LLC
BuyCompany 300 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%-.--%-.--%+21.72% 224M
+0.96%+1.16%-12.70%-12.33% 43.03B
+3.38%+6.98%+299.45%+531.90% 32.71B
-2.61%-2.83%+12.08%-17.66% 30.29B
+0.73%-1.83%+0.54%+32.24% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.49%+8.48% - - 13.54B
-0.35%+1.67%+54.68%+111.03% 13.35B
-1.09%-2.31%+3.49%+5.00% 12.97B
+0.47%-0.23%+108.20%+75.99% 12.11B
Average +0.48%+0.75%+53.34%+85.55% 21.27B
Weighted average by Cap. +0.68%+0.82%+60.63%+101.97%

Financials

2022 2023
Net sales - -
Net income -1.54M -1.33M -1.22M -1.15M -2.16M -146M -2.18M -14.48M -5.66M -71.46M -5.79M -5.67M -247M -1.18M -1.02M -937K -879K -1.65M -112M -1.67M -11.08M -4.33M -54.66M -4.43M -4.34M -189M
Net Debt -19.44M -16.75M -15.42M -14.47M -27.17M -1.84B -27.44M -182M -71.21M -900M -72.95M -71.4M -3.11B -18.88M -16.27M -14.97M -14.05M -26.38M -1.78B -26.65M -177M -69.14M -874M -70.83M -69.33M -3.02B
Logo Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Employees
27
  1. Stock Market
  2. Stocks
  3. MACK Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!